These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 33462831)

  • 21. Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.
    Patnaik A; Kang SP; Rasco D; Papadopoulos KP; Elassaiss-Schaap J; Beeram M; Drengler R; Chen C; Smith L; Espino G; Gergich K; Delgado L; Daud A; Lindia JA; Li XN; Pierce RH; Yearley JH; Wu D; Laterza O; Lehnert M; Iannone R; Tolcher AW
    Clin Cancer Res; 2015 Oct; 21(19):4286-93. PubMed ID: 25977344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selection of the Recommended Phase 2 Dose for Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1.
    Vugmeyster Y; Wilkins J; Koenig A; El Bawab S; Dussault I; Ojalvo LS; De Banerjee S; Klopp-Schulze L; Khandelwal A
    Clin Pharmacol Ther; 2020 Sep; 108(3):566-574. PubMed ID: 31955412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.
    Gibiansky E; Gibiansky L; Buchheit V; Frey N; Brewster M; Fingerle-Rowson G; Jamois C
    Br J Clin Pharmacol; 2019 Sep; 85(9):1935-1945. PubMed ID: 31050355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology.
    Ji Y; Jin JY; Hyman DM; Kim G; Suri A
    Clin Transl Sci; 2018 Jul; 11(4):345-351. PubMed ID: 29392871
    [No Abstract]   [Full Text] [Related]  

  • 25. [Pembrolizumab for the treatment of melanoma: updates and perspectives.].
    Chiarion Sileni V; Mandalà M; Queirolo P
    Recenti Prog Med; 2017 Dec; 108(12):528-531. PubMed ID: 29297903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pembrolizumab for the treatment of gastric cancer.
    Kamath SD; Kalyan A; Benson AB
    Expert Rev Anticancer Ther; 2018 Dec; 18(12):1177-1187. PubMed ID: 30280940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer.
    Segal NH; He AR; Doi T; Levy R; Bhatia S; Pishvaian MJ; Cesari R; Chen Y; Davis CB; Huang B; Thall AD; Gopal AK
    Clin Cancer Res; 2018 Apr; 24(8):1816-1823. PubMed ID: 29549159
    [No Abstract]   [Full Text] [Related]  

  • 28. Dosage of anti-PD-1 monoclonal antibodies: a cardinal open question.
    Sureda M; Calvo E; Mata JJ; Escudero-Ortiz V; Martinez-Navarro E; Catalán A; Rebollo J
    Clin Transl Oncol; 2021 Aug; 23(8):1511-1519. PubMed ID: 33583005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors.
    Razak AR; Cleary JM; Moreno V; Boyer M; Calvo Aller E; Edenfield W; Tie J; Harvey RD; Rutten A; Shah MA; Olszanski AJ; Jäger D; Lakhani N; Ryan DP; Rasmussen E; Juan G; Wong H; Soman N; Smit MD; Nagorsen D; Papadopoulos KP
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33046621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of covariate effects on pharmacokinetics of monoclonal antibodies in oncology.
    Bajaj G; Suryawanshi S; Roy A; Gupta M
    Br J Clin Pharmacol; 2019 Sep; 85(9):2045-2058. PubMed ID: 31140642
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting.
    Morrissey KM; Marchand M; Patel H; Zhang R; Wu B; Phyllis Chan H; Mecke A; Girish S; Jin JY; Winter HR; Bruno R
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1257-1267. PubMed ID: 31542806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection.
    Viala M; Vinches M; Alexandre M; Mollevi C; Durigova A; Hayaoui N; Homicsko K; Cuenant A; Gongora C; Gianni L; Tosi D
    Br J Cancer; 2018 Mar; 118(5):679-697. PubMed ID: 29438365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19.
    Goldstein DA; Ratain MJ; Saltz LB
    JAMA Oncol; 2020 Nov; 6(11):1694-1695. PubMed ID: 32459313
    [No Abstract]   [Full Text] [Related]  

  • 34. Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study.
    Shen L; Guo J; Zhang Q; Pan H; Yuan Y; Bai Y; Liu T; Zhou Q; Zhao J; Shu Y; Huang X; Wang S; Wang J; Zhou A; Ye D; Sun T; Gao Y; Yang S; Wang Z; Li J; Wu YL
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561638
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
    Schachter J; Ribas A; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank C; Petrella TM; Hamid O; Zhou H; Ebbinghaus S; Ibrahim N; Robert C
    Lancet; 2017 Oct; 390(10105):1853-1862. PubMed ID: 28822576
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ren S; Squires H; Hock E; Kaltenthaler E; Rawdin A; Alifrangis C
    Pharmacoeconomics; 2019 Sep; 37(9):1073-1080. PubMed ID: 30547369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Semimechanistically Based Modeling of Pembrolizumab Time-Varying Clearance Using 4 Longitudinal Covariates in Patients With Non-Small Cell Lung Cancer.
    Li H; Sun Y; Yu J; Liu C; Liu J; Wang Y
    J Pharm Sci; 2019 Jan; 108(1):692-700. PubMed ID: 30423341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance.
    Turner DC; Kondic AG; Anderson KM; Robinson AG; Garon EB; Riess JW; Jain L; Mayawala K; Kang J; Ebbinghaus SW; Sinha V; de Alwis DP; Stone JA
    Clin Cancer Res; 2018 Dec; 24(23):5841-5849. PubMed ID: 29891725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PET/CT Imaging of
    Li W; Wang Y; Rubins D; Bennacef I; Holahan M; Haley H; Purcell M; Gantert L; Hseih S; Judo M; Seghezzi W; Zhang S; van der Veen EL; Lub-de Hooge MN; de Vries EGE; Evelhoch JL; Klimas M; Hostetler ED
    Mol Imaging Biol; 2021 Apr; 23(2):250-259. PubMed ID: 33104972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Guiding dose selection of monoclonal antibodies using a new parameter (AFTIR) for characterizing ligand binding systems.
    Ahmed S; Ellis M; Li H; Pallucchini L; Stein AM
    J Pharmacokinet Pharmacodyn; 2019 Jun; 46(3):287-304. PubMed ID: 31037615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.